ライフサイエンスコーパス: myelocytic

1 T-cell, B-cell, and myelocytic and monocytic chimerism were also studied.

2 nd differentiated but immature cells of both myelocytic and monocytic lineages.

3 ortant role in the homeostatic regulation of myelocytic cell generation.

4 cell lines (JEG-3, ED27) but not in a human myelocytic cell line (HL60).

5 ts from transfection experiments using human myelocytic cell line (U937) demonstrated a direct relati

6 Wild-type HL-60, a transformed pro-myelocytic cell line, is very susceptible to apoptosis-i

7 s not inhibit phagocytosis by macrophage and myelocytic cell lines in vitro and is attenuated in an e

8 HL-60 myelocytic cells differentiated to surrogate PMNs respon

9 locytic leukemia (APL) was noted among acute myelocytic leukemia (AML) cases at the Los Angeles Count

10 g ATRA/ATO-based strategies to non-APL acute myelocytic leukemia (AML) is currently lacking.

11 ients who were recently diagnosed with acute myelocytic leukemia (AML) were assigned randomly to stan

12 ) have been evaluated in patients with acute myelocytic leukemia (AML), both as potential priming age

13 These included chronic myelocytic leukemia (CML) blast crisis K562 and HL-60/Bc

14 otein expression of kinases in K-562 chronic myelocytic leukemia (CML) cells elicited by treatment wi

15 Chronic myelocytic leukemia (CML) is a common neoplasm of hemato

16 ped progressive blast crisis (BC) of chronic myelocytic leukemia (CML) while receiving therapy with i

17 In patients with chronic myelocytic leukemia (CML), the breakpoint cluster region

18 mportant roles in the progression of chronic myelocytic leukemia (CML), we performed allelotype analy

19 ions (DLI) in patients with relapsed chronic myelocytic leukemia after allogeneic bone marrow transpl

20 elocytic leukemia and in some cases of acute myelocytic leukemia and acute lymphocytic leukemia, the

21 blood cells derived from patients with acute myelocytic leukemia and chronic myelocytic leukemia, whi

22 er survival in groups of patients with acute myelocytic leukemia and epithelial ovarian cancer who ha

23 n successfully administered to patients with myelocytic leukemia and has produced therapeutic effects

24 In most cases of chronic myelocytic leukemia and in some cases of acute myelocyti

25 Most cases of acute myelocytic leukemia are homozygous for the allele with t

26 Previous work showed that acute myelocytic leukemia blasts accumulate less long chain po

27 The HLA class I- and class II-negative myelocytic leukemia cell line K562 was transfected with

28 toire in four patients with relapsed chronic myelocytic leukemia who achieved a complete remission af

29 a RA-dependent manner in the NB-4, acute pro-myelocytic leukemia, and the MCF-7, breast carcinoma, ce

30 s with acute myelocytic leukemia and chronic myelocytic leukemia, which express BCR-Abl, demonstrate

31 ignificant promise in the treatment of acute myelocytic leukemia.

32 hematopoietic cell transplantation and acute myelocytic leukemia.

33 acute lymphoblastic leukemia, and 1 chronic myelocytic leukemia.

34 ment of acute childhood leukemia and chronic myelocytic leukemia.

35 clin A1 overexpression was observed in acute myelocytic leukemias, especially those that were at the

36 Although CD33 is expressed on acute myelocytic leukemic blast cells from about 90% of patien

37 its prompt downregulation is associated with myelocytic maturation.

38 E- and P-selectin ligands in leukocytes and myelocytic or monocytic leukemia cells are carried by tr

39 tients lacking gp91(phox) (X-CGD), the human myelocytic PLB-985 cell line, PLB-985 cells in which gp9

40 ansition from the promyelocytic stage to the myelocytic stage of neutrophil development, being indisp

41 y differentiate into granulocytes at the pro-myelocytic stage.